Management of multi- and extensively drug-resistant tuberculosis in Ukraine: how well are we doing?

N Lytvynenko; S Cherenko; Y Feschenko; M Pogrebna; Y Senko; A Barbova; M Manzi; O Denisiuk; A Ramsay; R Zachariah

doi:10.5588/pha.14.0035

Management of multi- and extensively drug-resistant tuberculosis in Ukraine: how well are we doing?

N Lytvynenko, S Cherenko, Y Feschenko, M Pogrebna, Y Senko, A Barbova, M Manzi, O Denisiuk, A Ramsay, R Zachariah

School of Medicine

Research output: Contribution to journal › Article › peer-review

17 Citations (Scopus)

Abstract

SETTING: A tertiary care facility in Ukraine, a high multi- and extensively drug-resistant tuberculosis (MDR/XDR-TB) burden country.

OBJECTIVES: To assess the management and treatment outcomes of MDR, pre-XDR-TB and XDR-TB.

DESIGN: Cohort study using programme data, 2006-2011.

RESULTS: Of 484 individuals with drug-resistant TB, 217 (45%) had MDR-, 153 (32%) pre-XDR- and 114 (24%) XDR-TB. Of all resistant types completing the intensive phase of treatment, 322 (67%) were alive and had culture converted. This included 157 (72%) with MDR- and 61 (54%) with XDR-TB. At the end of the continuation phase of treatment, 106 (22%) had treatment success and 378 (78%) had unfavourable outcomes, including 110 (23%) failures, 21 (4%) deaths, 71 (15%) losses to follow-up and 176 (36%) with an unknown outcome. This was associated with more than one lung cavity being affected, a history of treatment with second-line anti-tuberculosis drugs, poor adherence and XDR-TB. A total of 226 (47%) patients reported at least one adverse drug reaction, the most common being gastrointestinal and vestibular toxicity.

CONCLUSION: Outcomes of MDR- and XDR-TB were satisfactory in the intensive phase; however, this was not sustained during the ambulatory period. If we are to do better, urgent measures are needed to improve ambulatory management, including making safer, shorter and more effective drug regimens available.

Original language	English
Pages (from-to)	S67-72
Journal	Public health action
Volume	4
Issue number	Suppl 2
DOIs	https://doi.org/10.5588/pha.14.0035
Publication status	Published - 21 Oct 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.5588/pha.14.0035

Cite this

@article{199e5dd634ab438791e95a3bd3914a58,

title = "Management of multi- and extensively drug-resistant tuberculosis in Ukraine: how well are we doing?",

abstract = "SETTING: A tertiary care facility in Ukraine, a high multi- and extensively drug-resistant tuberculosis (MDR/XDR-TB) burden country.OBJECTIVES: To assess the management and treatment outcomes of MDR, pre-XDR-TB and XDR-TB.DESIGN: Cohort study using programme data, 2006-2011.RESULTS: Of 484 individuals with drug-resistant TB, 217 (45%) had MDR-, 153 (32%) pre-XDR- and 114 (24%) XDR-TB. Of all resistant types completing the intensive phase of treatment, 322 (67%) were alive and had culture converted. This included 157 (72%) with MDR- and 61 (54%) with XDR-TB. At the end of the continuation phase of treatment, 106 (22%) had treatment success and 378 (78%) had unfavourable outcomes, including 110 (23%) failures, 21 (4%) deaths, 71 (15%) losses to follow-up and 176 (36%) with an unknown outcome. This was associated with more than one lung cavity being affected, a history of treatment with second-line anti-tuberculosis drugs, poor adherence and XDR-TB. A total of 226 (47%) patients reported at least one adverse drug reaction, the most common being gastrointestinal and vestibular toxicity.CONCLUSION: Outcomes of MDR- and XDR-TB were satisfactory in the intensive phase; however, this was not sustained during the ambulatory period. If we are to do better, urgent measures are needed to improve ambulatory management, including making safer, shorter and more effective drug regimens available.",

author = "N Lytvynenko and S Cherenko and Y Feschenko and M Pogrebna and Y Senko and A Barbova and M Manzi and O Denisiuk and A Ramsay and R Zachariah",

year = "2014",

month = oct,

day = "21",

doi = "10.5588/pha.14.0035",

language = "English",

volume = "4",

pages = "S67--72",

journal = "Public health action",

issn = "2220-8372",

publisher = "International Union Against Tuberculosis and Lung Disease (The Union)",

number = "Suppl 2",

}

TY - JOUR

T1 - Management of multi- and extensively drug-resistant tuberculosis in Ukraine

T2 - how well are we doing?

AU - Lytvynenko, N

AU - Cherenko, S

AU - Feschenko, Y

AU - Pogrebna, M

AU - Senko, Y

AU - Barbova, A

AU - Manzi, M

AU - Denisiuk, O

AU - Ramsay, A

AU - Zachariah, R

PY - 2014/10/21

Y1 - 2014/10/21

N2 - SETTING: A tertiary care facility in Ukraine, a high multi- and extensively drug-resistant tuberculosis (MDR/XDR-TB) burden country.OBJECTIVES: To assess the management and treatment outcomes of MDR, pre-XDR-TB and XDR-TB.DESIGN: Cohort study using programme data, 2006-2011.RESULTS: Of 484 individuals with drug-resistant TB, 217 (45%) had MDR-, 153 (32%) pre-XDR- and 114 (24%) XDR-TB. Of all resistant types completing the intensive phase of treatment, 322 (67%) were alive and had culture converted. This included 157 (72%) with MDR- and 61 (54%) with XDR-TB. At the end of the continuation phase of treatment, 106 (22%) had treatment success and 378 (78%) had unfavourable outcomes, including 110 (23%) failures, 21 (4%) deaths, 71 (15%) losses to follow-up and 176 (36%) with an unknown outcome. This was associated with more than one lung cavity being affected, a history of treatment with second-line anti-tuberculosis drugs, poor adherence and XDR-TB. A total of 226 (47%) patients reported at least one adverse drug reaction, the most common being gastrointestinal and vestibular toxicity.CONCLUSION: Outcomes of MDR- and XDR-TB were satisfactory in the intensive phase; however, this was not sustained during the ambulatory period. If we are to do better, urgent measures are needed to improve ambulatory management, including making safer, shorter and more effective drug regimens available.

AB - SETTING: A tertiary care facility in Ukraine, a high multi- and extensively drug-resistant tuberculosis (MDR/XDR-TB) burden country.OBJECTIVES: To assess the management and treatment outcomes of MDR, pre-XDR-TB and XDR-TB.DESIGN: Cohort study using programme data, 2006-2011.RESULTS: Of 484 individuals with drug-resistant TB, 217 (45%) had MDR-, 153 (32%) pre-XDR- and 114 (24%) XDR-TB. Of all resistant types completing the intensive phase of treatment, 322 (67%) were alive and had culture converted. This included 157 (72%) with MDR- and 61 (54%) with XDR-TB. At the end of the continuation phase of treatment, 106 (22%) had treatment success and 378 (78%) had unfavourable outcomes, including 110 (23%) failures, 21 (4%) deaths, 71 (15%) losses to follow-up and 176 (36%) with an unknown outcome. This was associated with more than one lung cavity being affected, a history of treatment with second-line anti-tuberculosis drugs, poor adherence and XDR-TB. A total of 226 (47%) patients reported at least one adverse drug reaction, the most common being gastrointestinal and vestibular toxicity.CONCLUSION: Outcomes of MDR- and XDR-TB were satisfactory in the intensive phase; however, this was not sustained during the ambulatory period. If we are to do better, urgent measures are needed to improve ambulatory management, including making safer, shorter and more effective drug regimens available.

U2 - 10.5588/pha.14.0035

DO - 10.5588/pha.14.0035

M3 - Article

C2 - 26393102

SN - 2220-8372

VL - 4

SP - S67-72

JO - Public health action

JF - Public health action

IS - Suppl 2

ER -

Management of multi- and extensively drug-resistant tuberculosis in Ukraine: how well are we doing?

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this